All News

Glucagon-like peptide-1 receptor agonists have been associated with improvements in quality of life (QOL), restrained eating, and emotional eating behavior.

Jeff Goad, PharmD, MPH, discusses hesitancy for hepatitis vaccines and the necessary advice pharmacists can utilize to help patients manage these misconceptions.

Novavax’s COVID-19 vaccine has been available in the US under emergency use authorization since July 2022.

Researchers conducted a clinical review detailing the intersection of dermatology and suicide, explaining why skin conditions lead to increased risk of poor mental health.

Investigators note that the long-term effects of attention deficit/hyperactivity disorder (ADHD) medication for children remain lacking.

The announcement comes shortly after the company announced it had filed its second chapter 11 bankruptcy in under 2 years.

Jeff Goad, PharmD, MPH, discusses hepatitis viruses and the current vaccination schedules available for patients to stay protected.

Dihydroergotamine (Brekiya) is an acute treatment to help relieve migraine attacks, and it can come in nasal sprays, injections, and intravenous infusions.

The investigators hope to pursue a human vaccine in order to improve upon the already existing vaccines.

Investigators report that patients experience weight loss with a reduced weekly dosage of the glucagon-like peptide-1 (GLP-1).

Abbott’s continuous glucose monitoring system is the first to show a reduction in cardiovascular complication severity.

However, investigators find many gaps remaining in care for patients in relation to race, ethnicity, and disabilities.

Investigators also find that patients diagnosed with type 1 diabetes later in life do not have a better prognosis compared to those diagnosed earlier.

Investigators also found that nocturnal hypoglycemia is a strong predictor of daytime hypoglycemia.

Pharmacist-led interventions improve medication adherence compared with the usual care for patients with heart failure and type 2 diabetes.

Semaglutide resulted in a significant reduction in the risk of MACE within the first 3 months of treatment compared to placebo.

Patients with psychosis, depression, and anxiety exhibit higher rates of vaccine hesitancy.

Greg Miller, RPh, discussed the past, present, and future of the Inflation Reduction Act and key insights pharmacists should understand in order to keep up with the legislation.

In a phase 3 study, 57% of patients treated with icotrokinra achieved an Investigator's Global Assessment score of 1 or 0 and a grade 2 or more improvement at week 16.

Tirzepatide (Zepbound) demonstrated superiority compared to semaglutide (Wegovy) across the primary end point and 5 key secondary end points.

The order is set to make patients’ prescription costs similar to other nations with the lowest-priced drugs in the world.

Investigators find that unhealthy eating and inadequate or excessive sleeping duration could contribute to developing diabetic nephropathy.

Douglas Hoey, CEO of NCPA, discusses what independent pharmacies can do to handle an influx of patients and what the chain’s situation means for the pharmacy landscape.

Stanley V. Campbell, Jr., CEO of EagleForce Associates, Inc., and Yi Deng, PhD, Senior Vice President of Engineering at EagleForce, discuss the basics of AI and how it’s assisting with compliance.

The therapy achieved positive results during a phase 2b trial on the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score.

The therapy is currently under FDA review and has a PDUFA action date of May 22, 2025.

Angiotensin-converting enzyme inhibitors have been known to be more effective in decreasing the incidence of major adverse cardiac events for patients with diabetes.

Guselkumab is the first and only IL-23 inhibitor to demonstrate robust data as a fully subcutaneous regimen.